• Responsible for design and scale up of vaccine platform• Designed and optimized assays for testing in vitro potency• Performed basic molecular biology research on new viral vector systems

• Researched, designed, and characterized novel next generation lentiviral platforms• Conceptualized, cloned and validated viral vectors expressing select tumor associated antigens• Responsible for viral vector construction/cloning/manufacture/purification for all of R&D• Developed in vitro assays for assessment of novel lentiviral vectors• Explored and setup alternative vaccine platforms• Managed and maintained viral vector laboratory

• Designed and executed independent experiments for multiple vaccine platforms and disease targets• Optimized alphavirus replicon vectors through novel manipulation and rational design• Designed, cloned, and optimized the utility of novel viral vectors• Assisted in the scale-up of an RNA transcription process • Trained and on-boarded associates and interns• Attended/presented at project meetings and conferences

• Contributed to the development of novel vaccine delivery platform based on self-replicating RNA• Established in-house assays for the in vitro/in vivo evaluation of optimized viral vectors• Designed, constructed, and optimized vaccines for multiple targets and expression systems • Responsible for the bulk production of RNA vaccine material for animal studies• Managed and maintained laboratory

• Investigated the role of the cytidine deaminase enzyme, mouse APOBEC3 in restriction of HIV/MLV infections.• Researched the mechanism of HIV-1 envelope glycoprotein-independent binding of virus particles to dendritic cells, using a combination of molecular biology techniques, tissue culture techniques, and in vitro assays. • Trained and worked in Bio Safety Level 3